Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial

The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers.

Source: European Journal of Cancer - June 19, 2021 Category: Cancer & Oncology Authors: Valentina Guarneri, Maria V. Dieci, Gaia Griguolo, Federica Miglietta, Fabio Girardi, Giancarlo Bisagni, Daniele G. Generali, Katia Cagossi, Samanta Sarti, Antonio Frassoldati, Lorenzo Gianni, Luigi Cavanna, Graziella Pinotti, Antonino Musolino, Federico Tags: Original Research Source Type: research